MicroStrategy
MSTR
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
Meritage Homes
MTH
US Stock MarketDetailed Quotes
OCGN Ocugen
- 0.7743
- +0.0064+0.83%
Close Dec 20 16:00 ET
- 0.7701
- -0.0042-0.54%
Post 20:01 ET
225.57MMarket Cap-4.08P/E (TTM)
0.7999High0.7300Low21.58MVolume0.7510Open0.7679Pre Close16.68MTurnover7.51%Turnover RatioLossP/E (Static)291.32MShares2.105052wk High5.57P/B222.48MFloat Cap0.457852wk Low--Dividend TTM287.33MShs Float778.1999Historical High--Div YieldTTM9.10%Amplitude0.1700Historical Low0.7720Avg Price1Lot Size
About Ocugen Company
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.
Company Profile
SymbolOCGN
Company NameOcugen
Listing DateDec 3, 2014
Issue Price11.00
Founded2013
CEODr. Shankar Musunuri, M.B.A.,PhD
MarketNASDAQ
Employees65
Fiscal Year Ends12-31
Address11 Great Valley Parkway
CityMalvern
ProvincePennsylvania
CountryUnited States of America
Zip Code19355
Phone1-484-328-4701
Websitehttp://www.ocugen.com
Company Executives
- Name
- Position
- Salary
- Dr. Shankar Musunuri, M.B.A.,PhD
- Chairman of the Board and Chief Executive Officer
- 7.66M
- Arun Upadhyay, PhD
- Chief Scientific Officer and Head, Research, Development, and Medical
- --
- Dr. Huma Qamar, M.D.,PhD
- Chief Medical Officer
- --
- Ramesh Ramachandran
- Principal Financial Officer and Chief Accounting Officer
- --
- Kirsten Castillo, M.B.A.
- Independent Director
- 348.18K
- Dr. Junge Zhang, PhD
- Independent Director
- 335.56K
- Dr. Prabhavathi Fernandes, PhD
- Lead Independent Director
- 357.60K
- Uday B. Kompella, PhD
- Independent Director
- 341.82K
- Dr. Marna C. Whittington, PhD
- Independent Director
- 649.56K
- Michael Breininger, C.P.A.,M.B.A.
- Corporate Controller
- --
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.